Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05580770 · ClinicalTrials.gov registry record · Phase 1
Mirdametinib + BGB-3245 in Advanced Solid Tumors
A Phase 1 study, sponsored by SpringWorks Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT05580770 is a Phase 1 study that was terminated before completion, run by SpringWorks Therapeutics. The registered enrollment target is 23 participants.
The verdict
NCT05580770, a Phase 1 study, was terminated before completion, sponsored by SpringWorks Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with histologically confirmed, advanced (American Joint Committee on Cancer (AJCC) Stage III or IV) metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-cancer therapy including chemotherapy, immunotherapy, or appropriate targeted therapy, or for which there is no treatment available, or prior standard of care therapy was not tolerated.
Interventions
- DRUG Mirdametinib 2mg
- DRUG BGB-3245 5mg
- DRUG Mirdametinib 3mg
- DRUG Mirdametinib 4mg
- DRUG BGB-3245 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-02-03 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05580770
The ClinicalTrials.gov registry entry for NCT05580770 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SpringWorks Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Mirdametinib 2mg is the first listed.
NCT05580770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05580770 about?
NCT05580770 is a clinical study titled "Mirdametinib + BGB-3245 in Advanced Solid Tumors". A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with histologically confirmed, advanced (American Joint Committee on Cancer (AJCC) Stage III or IV) metastatic or unresectable solid cancer that is refractory ...
What is the current status of trial NCT05580770?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2023-02-03. Estimated completion is 2025-01-15.
What interventions are being tested in trial NCT05580770?
The interventions under investigation include: Mirdametinib 2mg (DRUG), BGB-3245 5mg (DRUG), Mirdametinib 3mg (DRUG), Mirdametinib 4mg (DRUG), BGB-3245 10mg (DRUG).
Who is sponsoring clinical trial NCT05580770?
This trial is sponsored by SpringWorks Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.